Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.48 |
| ▸ | IL2 | P60568 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.48 |
| ▸ | MDM4 | O15151 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | GRB2 | P62993 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29400507 | 1.00 | ALB (0.48) | ALBIL2PTPN1MDM4TP53 | |
| SCHEMBL5062433 | 1.00 | ALB (0.48) | ALBIL2PTPN1MDM4TP53 | |
| SCHEMBL8697104 | 0.90 | MDM4 (0.48) | PTPN1MDM4TP53SLC17A5MDM2 | |
| SCHEMBL14060727 | 0.88 | PTPN1 (0.43) | ALBIL2PTPN1MDM4TP53 | |
| SCHEMBL15762708 | 0.88 | PTPN1 (0.43) | ALBIL2PTPN1MDM4TP53 | |
| SCHEMBL9732381 | 0.87 | PTPN1 (0.54) | PTPN1MDM4TP53SLC17A5MDM2 | |
| SCHEMBL29500417 | 0.87 | PTPN1 (0.54) | PTPN1MDM4TP53SLC17A5MDM2 | |
| SCHEMBL29843110 | 0.87 | PTPN1 (0.54) | PTPN1MDM4TP53SLC17A5MDM2 | |
| SCHEMBL3868341 | 0.87 | PTPN1 (0.46) | ALBIL2PTPN1MDM4TP53 | |
| Catechol SCHEMBL18074826 | 0.86 | PTPN1 (0.53) | PTPN1MDM4TP53SLC17A5MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698551-A1 | NOVEL SMALL MOLECULE AGONISTS OF INSULIN RECEPTOR (INSR) AS ANTI-DIABETES DRUGS | The University of Hong Kong (CN) | 2026-02-25 | — | — | EP | disclosed |
| US-20260036595-A1 | STRUCTURE-BASED PEPTIDES FOR DETECTION OF TRANSTHYRETIN AMYLOID FIBRILS AND AGGREGATES IN PREECLAMPSIA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250362310-A1 | STRUCTURE-BASED PROBE FOR DETECTION OF TRANSTHYRETIN AMYLOID FIBRILS AND AGGREGATES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-27 | — | — | US | disclosed |
| CN-119119182-A | Novel SS-31 derivative, and preparation method and application thereof | 青岛山大齐鲁医院（山东大学齐鲁医院（青岛）） | 2024-12-13 | — | — | CN | disclosed |
| WO-2024217497-A1 | NOVEL SMALL MOLECULE AGONISTS OF INSULIN RECEPTOR (INSR) AS ANTI-DIABETES DRUGS | THE UNIVERSITY OF HONG KONG (CN) | 2024-10-24 | — | — | WO | disclosed |
| CN-116650617-A | Structure-based peptide inhibitors of alpha-synuclein aggregation | 加利福尼亚大学董事会 | 2023-08-29 | — | — | CN | disclosed |
| US-11390646-B2 | Structure-based peptide inhibitors of α-synuclein aggregation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-19 | — | — | US | disclosed |
| EP-2994476-B1 | STRUCTURE-BASED PEPTIDE INHIBITORS OF P53 AGGREGATION AS A NEW APPROACH TO CANCER THERAPEUTICS | UNIV CALIFORNIA (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-0528854-B1 | FLUOROGENIC PEPTIDES AND THEIR USE IN THE DETERMINATION OF ENZYMATIC ACTIVITIES | CARLSBERG AS (DK) | 1994-12-28 | — | — | EP | disclosed |
| EP-0528854-A1 | FLUOROGENIC PEPTIDES AND THEIR USE IN THE DETERMINATION OF ENZYMATIC ACTIVITIES. | CARLSBERG AS (DK) | 1993-03-03 | — | — | EP | disclosed |
| WO-1991016336-A1 | FLUOROGENIC PEPTIDES AND THEIR USE IN THE DETERMINATION OF ENZYMATIC ACTIVITIES | CARLSBERG A/S (DK) | 1991-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11390646-B2 | Structure-based peptide inhibitors of α-synuclein aggregation | SNCA, PARK7, IAPP | ALB 1267/4885IL2 2911/4885PTPN1 2024/4885 |
| US-20260036595-A1 | STRUCTURE-BASED PEPTIDES FOR DETECTION OF TRANSTHYRETIN AMYLOID FIBRILS AND AGGREGATES IN PREECLAMPSIA | TTR, APP, SERPINA3 | ALB 76/4885IL2 4149/4885PTPN1 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.